Absci Corp (ABSI) Total Debt to Equity Ratio

Absci (ABSI) designs unique antibodies using generative AI, which radically reduces laboratory testing costs. The company's operations are not subject to seasonality, although financial stability is tied to venture capital. The share price history on GURU.Markets demonstrates the 0.02 metric, while potential profit growth is constrained by significant software development costs.

For Absci (ABSI), financial stability is determined by the balance between borrowed funds and equity assets. By analyzing the total debt-to-equity ratio, an investor assesses the degree of leverage within the capital structure. This metric aggregates all liabilities, weighing them against the company's net worth. For this AI-drug developer, the indicator reflects the cost of scaling R&D infrastructure. The trend of this metric allows for an assessment of the business's risk of dependence on external financing while awaiting payments from pharmaceutical partners.